Literature DB >> 10335299

Risk factors for osteonecrosis in patients with type 1 Gaucher's disease.

S W Rodrigue1, D I Rosenthal, N W Barton, D Zurakowski, H J Mankin.   

Abstract

This study investigated 51 patients with Type 1 Gaucher's disease clinically and radiographically for the presence of osteonecrosis. Twenty-five female and 26 male patients with a mean age of 37 years were evaluated retrospectively for osteonecrosis of the proximal and distal femur, proximal tibia, and proximal humerus. All patients were examined before enzyme replacement therapy. Gender, age at diagnosis, prior splenectomy, hematocrit, platelet count, acid phosphatase level, radiographs of the long bones, and magnetic resonance quantitative chemical shift imaging of the spine were analyzed to see if any of these values or findings were associated with the presence of osteonecrosis. Splenectomy was an independent risk factor for the presence of osteonecrosis in three of the four major sites and was a multivariate risk factor for osteonecrosis of the proximal femur and tibia. Male gender was the other significant multivariate risk factor for osteonecrosis of the humerus and distal femur when all sites were taken into account.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10335299

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  9 in total

Review 1.  Clinically relevant therapeutic endpoints in type I Gaucher disease.

Authors:  C E Hollak; M Maas; J M Aerts
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

2.  Osteonecrosis of the femoral head: diagnosis and classification systems.

Authors:  Ho-Rim Choi; Marvin E Steinberg; Edward Y Cheng
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 3.  Gaucher disease.

Authors:  Aabha Nagral
Journal:  J Clin Exp Hepatol       Date:  2014-04-21

Review 4.  Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.

Authors:  T M Cox; J M F G Aerts; N Belmatoug; M D Cappellini; S vom Dahl; J Goldblatt; G A Grabowski; C E M Hollak; P Hwu; M Maas; A M Martins; P K Mistry; G M Pastores; A Tylki-Szymanska; J Yee; N Weinreb
Journal:  J Inherit Metab Dis       Date:  2008-05-23       Impact factor: 4.982

5.  Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; W Henley; K M Wyatt; V Nikolaou; S Waldek; D A Hughes; G M Pastores; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-03-18       Impact factor: 4.982

6.  Poor results of drilling in early stages of juxta-articular osteonecrosis in 12 joints affected by Gaucher disease.

Authors:  Ehud Lebel; Mici Phillips; Deborah Elstein; Ari Zimran; Menachem Itzchaki
Journal:  Acta Orthop       Date:  2009-04       Impact factor: 3.717

Review 7.  Osteonecrosis of the Femoral Head: an Updated Review of ARCO on Pathogenesis, Staging and Treatment.

Authors:  Jeremy T Hines; Woo Lam Jo; Quanjun Cui; Michael A Mont; Kyung Hoi Koo; Edward Y Cheng; Stuart B Goodman; Yong Chan Ha; Phillippe Hernigou; Lynne C Jones; Shin Yoon Kim; Takashi Sakai; Nobuhiko Sugano; Takuaki Yamamoto; Mel S Lee; Dewei Zhao; Wolf Drescher; Tae Young Kim; Young Kyun Lee; Byung Ho Yoon; Seung Hoon Baek; Wataru Ando; Hong Seok Kim; Jung Wee Park
Journal:  J Korean Med Sci       Date:  2021-06-21       Impact factor: 2.153

8.  Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage.

Authors:  Anneloes E Bohte; Laura van Dussen; Erik M Akkerman; Aart J Nederveen; Ralph Sinkus; Peter L M Jansen; Jaap Stoker; Carla E M Hollak
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

9.  Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study.

Authors:  L J Anderson; W Henley; K M Wyatt; V Nikolaou; D A Hughes; S Waldek; S Logan
Journal:  J Inherit Metab Dis       Date:  2014-02-11       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.